DCs (dendritic cells) are present in atherosclerotic lesions leading to vascular inflammation, and the number of vascular DCs increases during atherosclerosis. Previously, we have shown that the levels of circulating DCPs (DC precursors) are reduced in acute coronary syndromes through vascular recruitment. In the present study, we have investigated whether DCP levels are also reduced in stable CAD (coronary artery disease). The levels of circulating mDCPs (myeloid DCPs), pDCPs (plasmacytoid DCPs) and tDCP (total DCPs) were investigated using flow cytometry in 290 patients with suspected stable CAD. A coronary angiogram was used to evaluate a CAD score for each patient as follows: (i) CAD excluded (n = 57); (ii) early CAD (n = 63); (iii) moderate CAD (n = 85); and (iv) advanced CAD (n = 85). Compared with controls, patients with advanced stable CAD had lower HDL (high-density lipoprotein)-cholesterol (P = 0.03) and higher creatinine (P = 0.003). In advanced CAD, a significant decrease in circulating mDCPs, pDCPs and tDCPs was observed (each P < 0.001). A significant inverse correlation was observed between the CAD score and mDCPs, pDCPs or tDCPs (each P < 0.001). Patients who required percutaneous coronary intervention or coronary artery bypass grafting had less circulating mDCPs, pDCPs and tDCPs than controls (each P < 0.001). Multiple stepwise logistic regression analysis suggested mDCPs, pDCPs and tDCPs as independent predictors of CAD. In conclusion, we have shown that patients with stable CAD have significantly lower levels of circulating DCPs than healthy individuals. Their decrease appears to be an independent predictor of the presence of, and subsequent therapeutic procedure in, stable CAD.
INTRODUCTION
Atherosclerosis is a chronic inflammatory disease characterized by the invasion of immune cells, such as T-cells, monocytes, DCs (dendritic cells) and mast cells, into the vascular wall [1] . Over a decade ago, DCs were first described in atherosclerotic lesions as well as in healthy vascular intima [2, 3] . DCs are professional antigenpresenting cells with the unique ability to stimulate naïve as well as memory T-cells [4] . Therefore DCs play a critical role in many inflammatory conditions, particularly in autoimmune diseases [5] . DCs patrol the blood and the peripheral tissues to detect foreign, potentially harmful, antigens, and are able to initiate an immune response against them [6] . Two lineages of DC can be differentiated: mDCs (myeloid DCs; CD1c + and CD11c + ), which respond to bacteria and fungi, releasing IL (interleukin)-12, as well as pDCs (plasmacytoid DCs; CD303 + ), which release IFN-α (interferon-α) upon viral infection [6] . Both lineages can be detected in blood as DCPs (DC precursors), which have a high expression of HLA-DR, but lack the expression of co-stimulatory molecules, so that they are unable to activate T-cells. After invasion of (inflamed) tissue, they change their morphological appearance and are enabled to take up potential antigens (immature DCs), subsequently acquiring the ability to stimulate T-cells in an antigen-specific manner through the upregulation of co-stimulatory molecules (mature DCs).
More recently, it has been suggested that mDCs are critically involved in the progression and destabilization of atherosclerotic plaques [7] [8] [9] [10] . In the vessel wall, mDCs are activated by different atherogenic factors, such as oxidized LDL (low-density lipoprotein)-cholesterol [11] , nicotine [12] or AGEs (advanced glycation endproducts) [13] , enabling them to stimulate T-cells and probably leading to vascular inflammation. Proving this concept, Han et al. [14] recently demonstrated, in a vascular model, that mDCs are the most potent T-cell activators in atherosclerosis and are crucial for the immune reactions that occur in the vessel wall microenvironment.
Although investigations to date have focussed on the role of mDCs in atherosclerosis, Niessner et al. [15] described that pDCs are also present in atherosclerotic plaques, and there they stimulate T-cells against viral antigens.
During the progression of atherosclerosis, the number of mature mDCs and pDCs significantly increases in atherosclerotic lesions, and two independent mechanisms are responsible. First, in atherogenic areas of the vascular wall an increased recruitment of circulating DCPs was observed with accumulation particularly at the upstream shoulder of the atherosclerotic plaques [16, 17] . Certain atherogenic factors, such as hypoxia, oxidized LDLcholesterol or TNF-α (tumour necrosis factor-α) appear to enhance the transmigration of DCPs over the endothelium into the intima [18] . Secondly, studies have shown that the emigration of DCs from atherosclerotic lesions into the regional lymph nodes is reduced by certain pro-atherogenic conditions, such as the presence of oxidized LDL-cholesterol or PAF (platelet-activating factor) [19, 20] . Activated platelets have been shown to induce both vascular recruitment and maturation of circulating DCPs [21] .
In two previous studies [16, 22] , it was first shown that the level of circulating DCPs is significantly reduced in the blood of patients with ACS (acute coronary syndrome), indicating the possibility of their increased recruitment into the vascular wall. Patients with stable CAD (coronary artery disease) also appeared to have a reduction in circulating DCPs [16] , implicating that their decrease might not only be a transient effect in ACS, but could also represent a permanent state in stable CAD. Beyond alterations in the frequency of circulating DCPs, it has recently been shown [23] that, in patients with CAD, particularly those with ACS, cultivated DCs from blood monocytes had a significantly higher expression of co-stimulatory molecules, suggesting a greater ability of the DCs to stimulate T-cells. It has been suggested that differentiation of monocytes into mDCs might be an alternative way for their increase in the atherosclerotically altered vascular wall [23] .
The aim of the present study was to analyse in a larger scale clinical investigation whether circulating levels of mDCPs or pDCPs are significantly reduced in stable CAD, which factors are associated with any reduction and to determine whether the analysis of circulating mDCPs or pDCPs can predict the presence and stage of CAD.
MATERIALS AND METHODS

Study population
Between December 2005 and July 2007, 290 patients with suspected CAD, who underwent a coronary angiography at our clinic, were enrolled in the present study. Exclusion criteria were ACSs (unstable angina pectoris, new or dynamic ST segment changes, and/or troponin-I > 0.5 ng/ml) and non-cardiac diseases that could interfere with our analysis, including acute or chronic infections, malignancies, autoimmune diseases, hyperthyroidism and medication with immunosuppressive agents. Routine blood analyses were performed in our hospital laboratory, according to clinic standards. Standardized blood sampling for flow cytometric analysis was carried out at admission before coronary angiography and, in some of the patients, after 24 h. Immediately after blood withdrawal, samples were analysed by flow cytometry.
The study was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. Informed consent was obtained from all patients, and the study was approved by the institutional ethics committee.
Evaluation of the CAD score and subdivision into the study groups
For each patient, a CAD score was calculated. For this purpose, the coronary angiogram was analysed by two experienced investigators, and for each of the 15 coronary segments the maximum grade of stenosis was assessed, as described previously [24] , as follows: left main coronary artery (S5), the proximal (S6), middle (S7) and distal (S8) LAD (left anterior descending coronary artery), the first (S9) and second (S10) diagonal branch of the LAD, the proximal (S11), middle (S13) and distal (S15) CX (circumflex artery), the first (S12) and second (S14) obtuse marginal branch of the CX, and the proximal (S1), medial (S2), and distal (S3 and S4) RCA (right coronary artery). According to the maximum grade of stenosis, each segment received a point value: 0 % (0 point), 1-25 % (1 point), 26-50 % (2 points), 51-75 % (3 points) and > 75 % (4 points). The CAD score was calculated for each patient by counting up the point values in each coronary segment. According to the CAD score, patients were subdivided into the following groups: 0 (CAD excluded, i.e. coronary healthy; n = 57), 1-5 (early CAD; n = 63), 6-10 (moderate CAD; n = 85) and > 10 (advanced CAD; n = 85). Additionally, patients were subdivided according to the therapeutic recommendation from the coronary angiogram report into the following groups: 1, no therapy required (n = 48); 2, medication alone (n = 123); 3, PCI (percutaneous coronary intervention; n = 80); or 4, CABG (coronary artery bypass grafting; n = 44).
Serum analysis of hsCRP (high-sensitivity C-reactive protein)
The serum concentration of hsCRP was measured using an immunonephelometric assay on a BN II analyser (Dade Behring).
Identification of DCPs by FACS
The technique for the analysis of circulating mDCPs and pDCPs was developed by Ito et al. [25] and Dzionek et al. [26] , who have shown that FACS analysis of BDCA (blood dendritic cell antigen)-1 + and BDCA-2 + cells led to the isolation of cells expressing mDC-and pDC-specific markers respectively, and possess certain functions that are characteristic of DCs. This technique is provided in the Blood Dendritic Cell Enumeration kit TM (BDCA kit; Miltenyi Biotec), which was used in the present study.
Fresh blood samples were collected in tubes containing EDTA. Three-colour staining and FACS analysis were performed as described previously [16] . Briefly, 300 μl of blood was mixed with 20 μl of the anti-BDCA cocktail for DCP analysis, and another 300 μl of blood was mixed with 20 μl of the control cocktail for the isotype control. Subsequently, 10 μl of dead cell discriminator was added, and the samples were incubated for 10 min under a 60 W light bulb. Erythrocytes were removed using the red blood cell lysis solution (Miltenyi Biotec), following the fixation of the samples with the fix solution (Miltenyi Biotec).
FACS analysis was performed using a FACSCalibur flow cytometer with CellQuest software (Becton Dickinson). Since circulating DCPs comprise only 0.1-1 % of WBCs (white blood cells), a special gating strategy was used to accurately analyse mDCPs, pDCPs and tDCPs (total DCPs) ( Figure 1 ). For each sample, 2 × 10 5 WBCs were registered in region R1 defined by FSC (forward scatter) and SSC (side scatter). In region R2, granulocytes were excluded according to their high SSC, and monocytes, lymphocytes and dead cells were excluded according to their CD14, CD19 and propidium iodide staining respectively. In regions R3 and R4, circulating mDCPs and pDCPs were detected according to their specific staining for BDCA-1 and BDCA-2 respectively, and tDCPs were the sum of cells in regions R3 and R4. The relative cell number of circulating mDCPs, pDCPs and tDCPs were assessed as a percentage of WBCs. The absolute cell numbers (cells/μl) were calculated using their relative cell numbers multiplied by the WBC count.
Statistical analysis
Statistical analyses were performed using the SigmaStat 2.03 ® software (SPSS). Values are expressed as medians or proportions (%). P < 0.05 was considered statistically significant. The non-parametric Mann-Whitney rank sum test was used to compare numerical data (e.g. mDCP, pDCP or tDCP values) between the study groups, as well as for the subgroup analysis. Categorical clinical data (e.g. gender, atherogenic risk factors and medication) were compared between the study groups using a χ 2 test. Correlation analyses, e.g. circulating DCPs with the CAD score, were performed using the non-parametric Spearman rank order test. The predictive value of different parameters for a CAD was analysed using univariate and multivariate logistic regression analysis. For this purpose, CAD was binary encoded for each patient (all coronary stenosis < 50 %, '0'; and one or more coronary stenoses > 50 %, '1'), and was analysed as a dependent variable compared with other factors (e.g. mDCP, pDCP or tDCP values) as independent variables. Quantitative variables, such as the DCP values, creatinine or age, were binary encoded for the logistic regression analysis using the median calculated for all patients (individual value < median, '0'; individual value > median, '1'). ORs (odds ratios) and 95 % CIs (confidence intervals) were calculated. As mDCPs, pDCPs and tDCPs had a high correlation with each other, a separate multiple stepwise logistic regression analysis was performed for each of them, including all parameters in the univariate analysis.
RESULTS
Baseline characteristics
Clinical characteristics of patients with CAD are shown in Table 1 . Compared with coronary healthy individuals (CAD excluded; CAD score, 0), patients with CAD were significantly older (P < 0.001), were more often treated with statins (P < 0.001) or aspirin (P = 0.03), had lower HDL (high-density lipoprotein)-cholesterol (P = 0.03), and had higher creatinine (P = 0.003). In addition, more patients with CAD had diabetes mellitus
Figure 1 Representative dot plots showing the gating strategy used for the identification of circulating mDCPs, pDCPs and tDCPs by flow cytometry
Upper panels, DCP analysis; lower panels, isotype control. In region R1, peripheral blood mononuclear cells (WBCs) were separated from debris and platelets according to their typical FSC and SSC. In region R2, excluded were: granulocytes by SSC, B-lymphocytes by CD19 staining, monocytes by CD14 staining, and dead cells by propidium iodide staining. In regions R3 and R4, circulating mDCPs and pDCPs were detected according to their specific BDCA-1 and BDCA-2 staining respectively. The number of circulating tDCPs represents the sum of cells detected in regions R3+R4.
and hyperlipidaemia, as well as a trend towards higher hsCRP and leucocytes. Regarding the therapeutic procedure suggested in the coronary angiogram report, patients with mild CAD (score 1-5) rarely required a PCI (16 %), and PCI was performed in 41 % of patients with moderate CAD (score 6-10), whereas only 8 % of them were treated with CABG. In advanced CAD (score > 10), nearly an equal number of patients underwent PCI (39 %) or CABG (44 %) ( Table 1) .
Decrease in circulating DCPs according to the stage of CAD
Comparing patients with mild (CAD score, 1-5), moderate (CAD score, 6-10) or advanced (CAD score, > 10) CAD with coronary healthy individuals (CAD score, 0), a significant stage-dependent decrease in circulating mDCPs, pDCPs and tDCPs was observed ( Figure 2 ; for exact median values see Table 1 ). As relative as well as absolute numbers of circulating DCPs were reduced, we were able to exclude the possibility that their decrease was caused by a dilution phenomenon due to an increase of another WBC population. In a portion of the study patients, a second DCP analysis was performed after 24 h and showed that coronary angiography (n = 51) or PCI (n = 38) itself did not cause any alteration in the level of circulating DCPs (results not shown).
Decrease in circulating DCPs according to the required therapeutic procedure
In a second model, patients were subdivided into four different study groups according to the therapeutic procedure suggested in the coronary angiogram report, i.e. CAD excluded with no necessity of any therapy (1) compared with CAD to be treated with medication (2), PCI (3) or CABG (4). Compared with coronary healthy individuals or patients with CAD suggested to medication alone, patients with CAD requiring CABG or PCI had significantly reduced relative and absolute numbers of circulating mDCPs, pDCPs and tDCPs (Figure 3) .
Effect of atherogenic risk factors or current medication on circulating DCP levels
In a subgroup analysis (Table 2) , we investigated whether different clinical factors or pre-existing medical therapy influenced the levels of circulating DCPs. With regard to the age and gender of the patients, no significant changes were observed. In patients with hypertension or hyperlipidaemia, significantly lower levels of circulating pDCPs and tDCPs, and a trend towards lower mDCPs, were observed. Patients with diabetes mellitus also had a trend towards lower levels of mDCPs, pDCPs and tDCPs. No significant changes were observed for smoking or a family history of CAD. With regard to the current medication of the patients, a trend towards lower DCP levels was observed for statins, aspirin and β-blockers. Different serum parameters, such as LDL-cholesterol, HDL-cholesterol, hsCRP or creatinine, were not associated with any changes in circulating DCPs. As expected, higher blood leucocytes were associated with higher DCP levels.
Correlation of circulating DCPs and further serum parameters with the CAD score
To analyse whether circulating DCPs and other serum parameters are directly associated with CAD, correlation analyses were performed. These analyses showed a significant inverse correlation between the CAD score and circulating mDCP percentage ( Figure 4A ), pDCP percentage ( Figure 4B ) and tDCP percentage ( Figure 4C ). Further parameters which were significantly, but weakly, correlated with the CAD score were HDL-cholesterol ( Figure 4E ) and creatinine ( Figure 4F ). For hsCRP, only a trend towards a correlation with the CAD score was observed ( Figure 4D) ; however, an inverse correlation was observed between hsCRP and circulating mDCPs (r = − 0.27, P < 0.001), pDCP (r = − 0.19, P < 0.002) and tDCP (r = − 0.25, P = 0.001) levels. Comparing the different DC subtypes, circulating mDCPs and pDCPs had a strong significant correlation with each other (r = 0.55, P < 0.001).
Circulating DCPs as independent predictors of the presence of CAD
As shown in Table 1 and Figure 4 , different factors appeared to be associated with the presence of CAD. Thus we investigated next which factors had a predictive
Figure 2 Frequency of circulating mDCPs, pDCPs and tDCPs in different stages of CAD
Relative numbers of circulating mDCPs (A), pDCPs (B) and tDCPs (C) [as a percentage of peripheral blood mononuclear cells (% WBC)], and absolute numbers of circulating mDCPs (D), pDCPs (E) and tDCPs (F) (as cells/μl) are shown. The box plots indicate the median (line inside the box), 25th and 75th percentile (upper and lower boundary of box)
, and 10th and 90th percentile (whiskers outside box). ns, not significant. value for CAD. Univariate analyses showed that significant predictors of CAD were age > 66 years, diabetes mellitus, HDL-cholesterol < 46.5 mg/dl and hsCRP > 1.97 mg/dl ( Figure 5A ). Additionally, the reduction in circulating mDCPs < 0.21 % or < 15.2 cells/μl, pDCPs < 0.10 % or < 7.9 cells/μl and tDCPs < 0.33 % or (A) Several factors, such as age, diabetes mellitus, HDL-cholesterol, hsCRP, and relative and absolute numbers of circulating mDCPs, pDCPs and tDCPs, were identified to be predictive for the presence of CAD (coronary stenosis/stenoses > 50 %) as determined by univariate analysis. Other factors, such as male gender, hypertension and creatinine, appeared to be associated with CAD, but did not reach statistical significance. (B) Relative and absolute numbers of circulating mDCPs, pDCPs and tDCPs were analysed separately in multiple stepwise logistic regression analyses each together with the factors of the univariate analysis (results shown for the tDCP % analysis). In contrast with those factors, relative (mDCP, pDCP, and tDCP) and absolute (pDCP and tDCP) numbers of circulating DCPs remained as independent predictors of CAD. The ORs, 95 % CI and P value are shown on the right-hand side of each panel.
< 24.8 cells/μl were also predictive of CAD, and actually appeared to be the strongest predictors ( Figure 5A ). Male gender, hypertension and creatinine > 1.04 mg/dl might also be predictive of CAD, but failed to reach statistical significance. To analyse whether the decrease in circulating DCPs is a predictor of CAD independent of the other variables in the univariate analysis, multiple stepwise logistic regression analysis was performed. As circulating mDCPs, pDCPs and tDCPs had a high correlation with each other, separate multiple stepwise logistic regression analyses were performed for their relative and absolute values in a model, together with age, gender, diabetes mellitus, hypertension, HDLcholesterol, creatinine and hsCRP ( Figure 5B ). In these analyses, a decrease in circulating DCPs either as relative (mDCP, pDCP and tDCP) or absolute (pDCP and tDCP) values remained the only independent predictor of CAD.
DISCUSSION
mDCs have been implicated in the inflammatory processes related to atherosclerosis [16, 27] . It has been shown that they are present in atherosclerotic plaques, that their number increases in the vascular wall depending on the stage of atherosclerosis, and that they may promote plaque destabilization [7] [8] [9] . Apart from that, previous studies have independently shown that the level of circulating DCPs is decreased in the blood of patients with CAD, particularly those with ACS [16, 22] . The aim of our present study was to investigate whether the level of circulating DCPs is also altered in stable CAD.
Compared with previous studies [16, 22] , circulating DCPs were analysed in a larger number of patients with angiographically evaluated stable CAD, allowing us to investigate whether the decrease in circulating DCPs is associated with the stage of CAD, or any other clinical factors, and if their decrease is an independent predictor of coronary artery stenoses.
In the present study, we have shown a stage-dependent decrease in circulating mDCPs, pDCPs and tDCPs in patients with CAD compared with individuals of similar age, coronary risk factors and angiographically excluded CAD. In contrast with our previous study [16] , where we described a predominant decrease in circulating mDCPs in unstable CAD and acute STEMI (ST-elevation myocardial infarction), we have now found in patients with exclusively stable CAD a comparable decrease in both circulating mDCPs and pDCPs, as reported by Van Vre et al. [22] . The explanation for the discrepancy in the DCP results in stable CAD and STEMI appears to lie in the different migratory pattern of mDCPs and pDCPs. Although mDCPs are recruited to the sites of inflammation in response to inflammatory chemokines, pDCPs are attracted steadily by homoeostatic chemokines into the lymphatic tissue [28] . Proving this concept, in a previous study in patients with dengue fever, stable levels of circulating pDCPs but a significant reduction in circulating mDCP due to enhanced emigration into inflammatory lesions was shown [29] . Indeed, a dense infiltration of mDCs, but not pDCs, in necrotic myocardium of patients with STEMI has been found recently [30, 31] . In the study by Van Vre et al. [22] , patients with STEMI were excluded, similar to our present investigation, explaining the comparable pattern of DCP decrease observed in both of these studies. Van Vre et al. [22] described that mDCs are activated by hsCRP, leading to DC maturation and increased DC-induced T-cell stimulation, and that mDCs are co-localized with hsCRP in atherosclerotic lesions [22] . Consistent with those findings, in the present study we observed a significant correlation between circulating DCPs, particularly mDCPs, and serum hsCRP, indicating that hsCRP might be involved in mDCP recruitment into atherosclerotic lesions in CAD.
With regard to the therapeutic procedure, we compared patients with CAD who required CABG or PCI with those appointed to medication alone or in no need of any treatment. Patients who required CABG or PCI had significantly lower levels of circulating mDCPs, pDCPs and tDCPs compared with the other two groups, indicating that their levels might be predictive of the targeted therapy after coronary angiography. Skowasch et al. [32] have described the recruitment of mDCPs into the treated lesion after PCI, suggesting that these cells are responsible for in-stent restenosis; however, in our present study, we were not able to detect any differences in the level of circulating DCPs in PCI-treated patients before and 24 h after PCI.
Compared with other studies published previously [16, 22] , the larger number of patients in our present study allowed us to perform a detailed subgroup analysis. We observed significantly lower levels of circulating pDCPs and tDCPs, and a trend towards lower mDCPs, in patients with hypertension or hyperlipidaemia. In addition, patients with diabetes mellitus had a trend towards lower mDCPs, pDCPs and tDCPs. An important aspect of the subgroup analysis is that patients with a family history of CAD had no reduction in levels of circulating DCPs, indicating that lower levels of DCPs are not a genetically determined factor for the development of CAD. A trend towards lower DCP levels was observed in patients treated with statins, aspirin and β-blockers; however, as shown in Table 1 , a significantly greater number of patients with CAD than controls were treated with aspirin or statins, so that the higher percentage of patients with CAD in the corresponding treatment groups (Table 2) is most likely to be responsible for the observed slightly lower levels of circulating DCPs in those groups, and a drug-induced effect can be excluded. Several factors have been described to be predictive of the presence of significant coronary stenoses in patients with suspected CAD and of the cardiovascular risk in patients with known CAD. It has been shown that lipoprotein(a) [33, 34] , lipoprotein-associated phospholipase A 2 [35] , total and differential leucocyte counts [36] , leptin [37] , serum glycated albumin [38] and hsCRP [39] are significantly associated with, and are predictive of, stable CAD. In those studies, it was shown in univariate analyses that certain clinical and serological factors, such as age, male gender, diabetes mellitus, hypertension, HDL-cholesterol, creatinine and hsCRP, were predictors of the presence of stable CAD [33, 36, 38, 39] . However, most of those factors are associated with each other, so that even established atherogenic markers, such as hsCRP, IL-6 and TNF-α, lost their independent predictive value for stable CAD in multivariate analysis after adjusting for conventional CAD risk factors [40] . In contrast, large-scale clinical studies have shown that hsCRP, IL-6 and several other factors are well-established predictors of future ischaemic cardiovascular events in patients with higher risk for or known CAD [41, 42] .
In our present study, we investigated whether the decrease in circulating DCPs is predictive of the presence of stable CAD. As a first step, we investigated which factors are associated with stable CAD using correlation analysis. Compared with hsCRP, HDL-cholesterol and creatinine, we observed a higher significant correlation of circulating mDCPs, pDCPs and tDCPs with the CAD score. Subsequently, we performed logistic regression analyses to investigate whether the decrease in circulating DCPs is a predictor of the presence of significant coronary artery stenoses. In univariate analysis, several factors, such as older age, diabetes mellitus, low HDL-cholesterol, high hsCRP, and reduced relative and absolute levels of circulating mDCPs, pDCPs and tDCPs, were predictors of CAD. Male gender, hypertension and elevated creatinine appear to have a predictive value as well, but did not reach statistical significance. In multivariate analyses, only the reduction in circulating mDCPs, pDCPs or tDCPs remained as independent predictors of significant CAD.
The reason for the decrease in circulating DCPs could not be clarified in our present study. Several explanations are possible, such as (i) reduced production of DCPs in the bone marrow, (ii) increased apoptosis of circulating DCPs, or (iii) enhanced recruitment and higher turnover of circulating DCPs in atherosclerotic lesions. There is no evidence for the first or the second explanation, as the level of other leucocyte subpopulations are not reduced in the blood of patients with CAD. However, several studies do exist supporting the third explanation. First, it has been shown that mDCs and pDCs accumulate in vascular lesions dependent on the stage of atherosclerosis [7] [8] [9] . Secondly, it has been suggested that mDCP recruitment from blood into the intima is induced by several atherogenic factors, such as oxidized LDL-cholesterol, hypoxia, TNF-α or nicotine [12, 18] . Thirdly, recirculation of mDCs from the vascular wall into the blood is suppressed by lysophosphatidic acid or PAF in atherosclerosis [19] .
In conclusion, the results of our present study show a significant decrease in circulating levels of mDCPs, pDCPs and tDCPs in patients with CAD with a stable clinical manifestation. The extent of their reduction is associated with the stage and with the recommended therapeutic procedure for CAD. Atherogenic risk factors, such as hypertension or hyperlipidaemia, might affect the level of circulating DCPs as well. In multiple stepwise logistic regression analysis we have shown that, in contrast with other classical predictors, only the decrease in circulating mDCPs, pDCPs and tDCPs remains as an independent predictor of significant CAD. Thus analysis of circulating DCPs might be useful for the diagnosis of CAD. Future prospective studies will be necessary to investigate whether the decrease in circulating DCPs is also predictive of future ischaemic cardiovascular events in patients with a high risk of or known CAD.
